CeleCor Therapeutics
Del Mar, US · Founded 2017 · Delaware corporation
Find your way into CeleCor Therapeutics
126 people in our graph share verified history with the CeleCor Therapeutics team — schools, employers, funds. One of them is your warm intro.
Scott Billerunlockedknows Robert Hillman · together at Massachusetts Institute of Technology (overlapped)
×2knows the team · via Massachusetts Institute of Technology
×8knows the team · via Stanford University
knows the team · via ActivX Biosciences
Celecor develops zalunfiban (Disaggpro), an investigational platelet inhibitor drug designed for rapid subcutaneous administration by first responders in pre-hospital treatment of STEMI heart attacks. The company focuses on acute cardiovascular care for patients experiencing the most severe form of heart attack.
Founders & leadership
CeleCor Therapeutics was founded in 2017 by Barry S. Coller, MD and Robert Hillman, PhD.
BS
Barry S. Coller, MDChair, Medical & SAB, Co-Founder, and Inventor of zalunfiban
RH
Robert Hillman, PhDPresident & CEO, Co-Founder
PB
Peter B. FinnSecretary
RH
Robert HillmaninCo-Founder, President and CEORobert Hillman is President and Treasurer at CeleCor Therapeutics, where he leads development of an investigational platelet inhibitor for pre-hospital treatment of acute heart attacks. He has over six years of experience in pharmaceutical and medical device development, with background in medical diagnostics, drug delivery systems, and regulatory affairs, including FDA and CE Mark approvals.
RS
Robert S. Hillman, Ph.D.Named on SEC filing
Board
JL
Jack LiefMember, Board of Directors
AR
Andreas RitziCo-Founder; Member, Board of Directors
Reported raises · per SEC filings
Form D private placements$58.4M disclosed across 3 of 4 rounds · 2017–2026
▶$11.9MraisedJul 2026 · 17 investors · PharmaceuticalsRule 506(b)
▶$11.9MraisedJul 2026 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert S. Hillman, Ph.D.Executive Officer, Director
- Andreas RitziDirector
- Jack LiefDirector
- Peter B. FinnExecutive Officer
- Offering amount
- $15M
- Amount sold
- $11.9M
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$45.5MraisedAug 2024 · 11 investors · BiotechnologyRule 506(b)
▶$45.5MraisedAug 2024 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jack LiefDirector
- Peter B. FinnExecutive Officer
- Andreas RitziDirector
- Robert HillmanExecutive Officer, Director
- Offering amount
- $45.5M
- Amount sold
- $45.5M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedMay 2021 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedMay 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jack LiefDirector
- Andreas RitziDirector
- Peter B. FinnExecutive Officer
- Robert HillmanExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1M
- Minimum investment
- $250K
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$25MofferedMay 2017 · 5 investors · BiotechnologyRule 506(b)
▶$25MofferedMay 2017 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andreas RitziDirector
- Peter B. FinnExecutive Officer
- Caspar F.V. SturmDirector
- Robert S. HillmanExecutive Officer, Director
- Offering amount
- $25M
- Minimum investment
- $500K
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapCapricor21 shared keywordsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
Arecor14 shared keywordsAreCor develops proprietary pharmaceutical products for diabetes, obesity, and cardiometabolic diseases using its Arestat technology platform. The company targets areas of high unmet patient need in high-value therapeutic markets.
Bioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Xylocor13 shared keywordsXyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.
Companies competing with CeleCor Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does CeleCor Therapeutics do?
- Celecor develops zalunfiban (Disaggpro), an investigational platelet inhibitor drug designed for rapid subcutaneous administration by first responders in pre-hospital treatment of STEMI heart attacks. The company focuses on acute cardiovascular care for patients experiencing the most severe form of heart attack.
- Who founded CeleCor Therapeutics?
- CeleCor Therapeutics was founded by Barry S. Coller, MD, Robert Hillman, PhD in 2017.
- How much funding has CeleCor Therapeutics raised?
- CeleCor Therapeutics has disclosed $58.4M raised across 3 of its 4 known rounds.
- Where is CeleCor Therapeutics headquartered?
- CeleCor Therapeutics is headquartered in Del Mar, US.